Datavant, a leading health data platform, has announced an expanded collaboration with Boehringer Ingelheim to strengthen the pharmaceutical company’s real-world evidence (RWE) capabilities. This strategic partnership aims to enhance clinical development and commercial strategy across 75 additional clinical trials and multiple new molecular entities (NMEs) by leveraging Datavant’s privacy-preserving tokenization and advanced data connectivity technologies.
The collaboration underscores the increasing importance of secure, connected data in transforming patient care. Using Datavant Connect powered by AWS Clean Rooms, Boehringer Ingelheim will be able to efficiently explore and assess third-party data sources without transferring or sharing underlying data, streamline data discovery, transformation, and linkage within its secure research environment, and generate deeper insights across the entire patient journey—from clinical development through post-launch performance.
Arnaub Chatterjee, President and GM of Life Sciences, Ecosystem, and Public Sector at Datavant, stated that the partnership represents a milestone in revolutionizing patient care through a pioneering data strategy. He emphasized that by enabling secure and efficient data linkage at scale, Boehringer Ingelheim is setting a new standard for medical research and demonstrating how technology can reshape healthcare and improve outcomes.
Echoing this sentiment, Paul Petraro, Executive Director and Head of the Real World Evidence Analytics Center of Excellence at Boehringer Ingelheim, highlighted that the investment in real-world data reflects the company’s commitment to using cutting-edge technologies to advance medical research. He noted that by expanding this approach across more trials and product launches, Boehringer Ingelheim aims to develop more personalized and cost-effective treatments that can significantly transform patient care.
To ensure seamless integration with Boehringer Ingelheim’s research infrastructure, the partnership will implement tokenization through a phased rollout. The initiative's key objectives include establishing a robust framework to guide future studies and demonstrating the value of cloud-based tokenization and RWE strategies to the broader pharmaceutical industry.
Click here to read the original news story.